KLOW

KLOW is a product name for four peptides sold together in one vial: GHK-Cu, BPC-157, TB-500, and KPV. It is not a compound of its own, and the components are studied individually. A verified vial label lists 80 mg total, with GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg.

Community practice reaches for KLOW to reconstitute one product instead of four. GHK-Cu is studied for skin remodeling and collagen ¹; BPC-157 and TB-500 are the repair pairing ²; KPV is studied for anti-inflammatory signaling ³. This convenience is the main reason people buy a single blend rather than separate vials.

GHK-Cu

GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, an endogenous tripeptide released during tissue remodeling ¹. It is studied for collagen and elastin production, skin aging, wound healing, and anti-inflammatory and antioxidant actions ⁵. Human evidence is strongest for topical cosmetic use; there are no human efficacy data for musculoskeletal or injectable indications ⁷.

BPC-157

BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein ⁸. It is studied for tendon and ligament healing, gastrointestinal cytoprotection, vascular repair, and angiogenesis ². The evidence is mainly animal and cell work, with only uncontrolled human pilot studies ⁹.

TB-500

TB-500 is the synthetic N-acetylated 17-23 fragment of thymosin beta-4, the actin-binding region of the parent peptide ¹⁴. It is studied for cell migration, wound healing, and tendon repair ². Direct TB-500 evidence is limited to one rat tendon study; most claims are extrapolated from the full-length parent peptide ¹⁶.

KPV

KPV is the C-terminal tripeptide of alpha-MSH, known as Lys-Pro-Val ³. It is studied for anti-inflammatory signaling, intestinal epithelial protection, and skin barrier repair ³. All evidence is preclinical or in-vitro; no human clinical trials have been published ²⁰.

KLOW's components overlap around wound repair, angiogenesis, and inflammation control, but they emphasize different parts of the process. BPC-157 is mainly a vascular and nitric-oxide signaling agent in the available studies ¹¹; TB-500 acts through actin-mediated cell migration ¹⁵; GHK-Cu acts through collagen and extracellular-matrix remodeling ¹; KPV acts through NF-kB suppression and anti-inflammatory signaling ³. This division of labor is mechanistically plausible.

Pairwise data are limited. In a rat Achilles tendon study, BPC-157 plus TB-500 provided no additive benefit over either peptide alone, suggesting shared downstream pathways ². GHK-Cu and BPC-157 are commonly stacked in community protocols and are described as complementary, but no direct combination studies exist ²³. KPV has a distinct anti-inflammatory mechanism and has not been studied with the other components ²⁰. No published study has tested this exact combination.

Component-level evidence supports the two broad uses KLOW is bought for: tissue repair and skin remodeling. Human findings remain stronger for GHK-Cu in cosmetic skin use than for the repair-focused components.

Use / component	Human evidence	Animal and cell evidence
Tissue repair: BPC-157	Uncontrolled pilot studies only, no randomized controlled trials 9.	Rat tendon and ligament models show improved healing 2; cell studies show endothelial proliferation and angiogenesis 11.
Tissue repair: TB-500	No direct human musculoskeletal trials 7.	One rat Achilles study showed improved maximum load to failure and histology 2; actin-based cell migration is established for the parent peptide 15.
Skin remodeling: GHK-Cu	Small aesthetic RCTs and meta-analyses report wrinkle and skin outcomes 5; injectable musculoskeletal evidence absent 7.	Fibroblast collagen synthesis in vitro 1; scald wound healing in mice 25.
Inflammation/barrier: KPV	No human trials 20.	Colitis and keratinocyte studies show reduced inflammatory markers and improved barrier function 3; oral nanoparticles improved colitis in mice 26.

KLOW's composition is fixed by the vial label. GHK-Cu makes up 63% of the vial contents, while BPC-157, TB-500, and KPV each make up 13%. GHK-Cu therefore dominates the product.

Because all four peptides are dissolved together, a single fixed-volume draw delivers all four components in proportion. No individual component can be adjusted on its own, and choosing a draw based on one component fixes the amount of every other component. The label records a composition; it does not by itself prove the contents are correct or sterile.

Community protocols for lyophilized peptides typically use bacteriostatic water as the diluent. Gentle mixing is preferred because shaking or jetting solvent can damage peptide structure; GHK-Cu is oxidation-sensitive, and loss of its blue color is a sign of copper dissociation ⁴.

Storage guidance from component studies is conservative. Lyophilized vials are generally kept frozen at -20 °C for long-term stability (community protocol). After reconstitution, refrigerated storage is standard, and studies with TB-500 show degradation in serum within a week at refrigerator or room temperature ²⁸. KPV degrades to a diketopiperazine under acid, alkali, or oxidative stress ²⁹. Across components, the most conservative published guidance is to keep reconstituted vials refrigerated and use them within roughly 14 days.

Component side effects

• GHK-Cu: Topical cosmetic use has a long favorable safety record ²³. Injectable human safety data are absent ⁷; copper delivery adds a route-specific concern ³², particularly in Wilson's disease or other copper-handling disorders (practitioner consensus).
• BPC-157: Published uncontrolled human pilots reported no adverse events ²⁴. Long-term safety is unstudied, and a theoretical angiogenesis-related cancer concern remains unresolved because pro-angiogenic and anti-tumor findings conflict ¹¹.
• TB-500: No human safety data exist for the fragment itself ¹⁶. The parent peptide had no safety signal in one myocardial infarction RCT, but that trial does not cover TB-500 directly ³⁷. Preclinical work links thymosin beta-4 to tumor cell migration and coagulation pathway effects, which remain theoretical for TB-500 ³⁸.
• KPV: No human safety trials exist. Preclinical formulations are described as nontoxic and biocompatible in intestinal and skin models ¹⁸. MC1R-based pigmentation changes and PepT1 transporter competition are theoretical concerns ³.

Interactions and higher-risk groups

Combining compounds combines their unknowns. BPC-157 plus TB-500 has no additive benefit in one animal study, so the interaction model is not synergy ². GHK-Cu and BPC-157 are common community stacks without direct interaction data ²³. KPV's anti-inflammatory pathway is mechanistically distinct but unstudied in combination ²⁰. Product quality is the most concrete risk across all four components: unapproved injectable peptides have documented contamination, mislabeling, and inaccurate dosing ³⁵. Higher-risk groups are flagged in the component safety profiles rather than as a blend-specific finding. Active malignancy is a relative contraindication for BPC-157 and TB-500 because the pro-angiogenic and tumor findings are unresolved ¹¹. Active malignancy is an absolute contraindication for GHK-Cu by practitioner consensus. Pregnancy and breastfeeding are avoided by practitioner consensus because no reproductive data exist. Bleeding disorders are a relative caution for TB-500 based on platelet and coagulation pathway effects ³⁹. Tested competitive athletes are prohibited from use because TB-500 and BPC-157 fall under WADA category S0 ⁴³, and KPV also falls under S0 as an unapproved substance ⁴⁴.

None of KLOW's components is approved as a drug for human therapeutic use in the United States. GHK-Cu is lawful as a cosmetic ingredient but lacks FDA drug approval ³⁰. BPC-157 is unapproved, and the FDA has determined it unsafe for compounding ⁴⁵. TB-500 is unapproved and is banned under WADA category S0, along with BPC-157, because neither has governmental approval for human therapeutic use ⁴³. KPV has no marketing authorization in any reviewed jurisdiction and falls into the S0 non-approved category in WADA terms ⁴⁴.

A blend carries the most restrictive status among its components. For KLOW, that means the product is not approved as a medicine, and the presence of TB-500 and BPC-157 makes it prohibited in sport under WADA S0 at all times.